Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CP-675,206 (Tremelimumab)
CP-675, 206 · 10 trials · 11 indications
| Arm | Type | Description |
|---|---|---|
| B | ACTIVE_COMPARATOR | Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice) |
| A | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | Drug: CP-675,206 (Tremelimumab) |
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| 15 mg/kg CP-675,206 | EXPERIMENTAL | - |
| 10 mg/kg | EXPERIMENTAL | pts treated at 10 mg/kg dose level on a monthly regimen |
| 15 mg/kg | EXPERIMENTAL | pts treated at 15 mg/kg dose level on a quarterly regimen |
| CP-675,206 and gemcitabine | EXPERIMENTAL | - |
| Commercial Formulation | EXPERIMENTAL | Commercial Formulation |
| Current Formulation | EXPERIMENTAL | Current Formulation |
| Name | Type | Description |
|---|---|---|
| dacarbazine | DRUG | decarbazine 1000 mg/m2 IV Q 21 days x 12 |
| CP-675,206 | DRUG | CP-675,206 15 mg/kg IV Q 90 days x 4 |
| temozolomide | DRUG | temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12 |
| CP-675,206 (Tremelimumab) | DRUG | 15 mg/kg IV every 3 months as long as required |
| best supportive care | DRUG | As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy |
| CP-675,206 and gemcitabine | DRUG | Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first. |
| SU011248 | DRUG | SU011248 administered at a dose of 37.5mg/day every day. |
| CP-675,206 and leuprolide acetate and bicalutamide | DRUG | - |
| leuprolide acetate and bicalutamide | DRUG | - |
Inclusion Criteria: * Surgically incurable melanoma, either Stage IV or IIIC with N3 status for regional lymph nodes and in-transit or satellite lesions. * Serum lactic acid dehydrogenase (LDH) \<= 2 x ULN * ECOG performance status of 0 or 1 Exclusion Criteria: * Received any systemic therapy for...
Top 20 of 48 competitors
CP-675,206 is an investigational oncology drug also known as tremelimumab. It is being developed by AstraZeneca PLC (ticker AZN) and has been studied in cancers including non-small-cell lung carcinoma, renal cell carcinoma, colorectal neoplasms, melanoma, and pancreatic cancer. It is in Phase 2 development.
CP-675,206 has been studied in several cancer types, including non-small-cell lung carcinoma, renal cell carcinoma, colorectal neoplasms, malignant melanoma, melanoma, and pancreatic cancer. It remains an investigational agent in Phase 2 development and is not described as approved for any indication.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of CP-675,206. The company has sponsored clinical studies of the agent in pancreatic cancer, melanoma, renal cell carcinoma, and other tumor types.
CP-675,206 is in Phase 2 development. The program includes completed Phase 1 and Phase 2 studies, and no active trials are currently listed. It is an investigational agent and is not described as FDA approved.
Completed studies include NCT00556023, a Phase 1 trial of CP-675,206 with gemcitabine in advanced pancreatic cancer; NCT00431275, a Phase 1 comparison of two CP-675,206 formulations in melanoma; NCT00378482, a Phase 2 rollover study; and NCT00372853, a Phase 1 dose-finding study in metastatic renal cell carcinoma.
Yes, CP-675,206 is also known as tremelimumab. The names refer to the same agent, and combination regimens studied with it include CP-675,206 and gemcitabine, as well as CP-675,206 with leuprolide acetate and bicalutamide.